泌尿病理学、肿瘤学与影像学的生物标志物、分子与技术进展
该综述阐述了泌尿病理学中生物标志物与分子检测诊断效用的扩展,以及泌尿肿瘤学、外科实践和影像学技术进展的适应。通过聚焦肾细胞癌新亚型、嗜铬细胞瘤和前列腺癌的诊断工作,展示了免疫组化在鉴别诊断中的应用及靶向基因表达面板预测术后复发的早期研究结果。机构内病理科与泌尿外科及介入放射科合作探索术中冰冻切片、微创腹股沟淋巴结清扫及影像引导穿刺活检等应用。
要点
- 泌尿病理诊断中生物标志物与分子检测的应用范围正在扩大。
- 免疫组化有助于肾穿刺活检、前列腺导管内癌和淀粉样变的鉴别诊断。
- 靶向基因表达面板预测前列腺癌术后复发已有早期 encouraging 结果。
核心结论
- 多学科协作方法可增强临床管理与研究,并优化泌尿疾病患者的照护。
研究设计与样本
- 综述性文章,通过精选疾病实体展示诊断工作趋势,未报告系统检索范围或样本量。
主要发现
- 新 recognized 的肾细胞癌、嗜铬细胞瘤和前列腺癌亚型中,部分具有独特的染色体易位、基因丢失或突变。
- 靶向基因表达面板预测前列腺癌术后复发的早期研究显示了 encouraging 结果。
临床怎么用
- 病理学家可与泌尿外科医生和介入放射科医生合作,探索术中冰冻切片用于机器人前列腺切除术中的切缘和神经保留。
- 可探索微创视频镜下腹股沟淋巴结清扫术,并改进影像引导下穿刺活检和冷冻治疗以及蓝光/荧光膀胱镜检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Urologic pathology is evolving rapidly. Emerging trends include the expanded diagnostic utility of biomarkers and molecular testing, as well as adapting to the plethora of technical advances occurring in genitourinary oncology, surgical practice, and imaging. We illustrate those trends by highlighting our approach to the diagnostic workup of a few selected disease entities that pathologists may encounter, including newly recognized subtypes of renal cell carcinoma, pheochromocytoma, and prostate cancer, some of which harbor a distinctive chromosomal translocation, gene loss, or mutation. We illustrate applications of immunohistochemistry for differential diagnosis of needle core renal biopsies, intraductal carcinoma of the prostate, and amyloidosis and cite encouraging results from early studies using targeted gene expression panels to predict recurrence after prostate cancer surgery. At our institution, pathologists are working closely with urologic surgeons and interventional radiologists to explore the use of intraoperative frozen sections for margins and nerve sparing during robotic prostatectomy, to pioneer minimally invasive videoscopic inguinal lymphadenectomy, and to refine image-guided needle core biopsies and cryotherapy of prostate cancer as well as blue-light/fluorescence cystoscopy. This collaborative, multidisciplinary approach enhances clinical management and research, and optimizes the care of patients with urologic disorders.
引用
- Ellis CL, Harik LR, Cohen C, et al. Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging. Arch Pathol Lab Med. 2017. PMID: 28157406. doi:10.5858/arpa.2016-0263-SA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。